Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

2024年 6月 11日

Read More

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

2024年 5月 22日

Read More

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China

2024年 5月 20日

Read More

Zai Lab Announces Participation in May and June Investor Conferences

2024年 5月 16日

Read More

Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

2024年 5月 14日

Read More

Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA

2024年 5月 12日

Read More

Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates

2024年 5月 08日

Read More

Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024

2024年 4月 15日

Read More